Search: onr:"swepub:oai:DiVA.org:umu-124512" > Association of a Lo...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06022naa a2200913 4500 | |
001 | oai:DiVA.org:umu-124512 | |
003 | SwePub | |
008 | 160815s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1245122 URI |
024 | 7 | a https://doi.org/10.1001/jamaneurol.2016.11142 DOI |
040 | a (SwePub)umu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Fogh, Isabella4 aut |
245 | 1 0 | a Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis |
264 | 1 | b American Medical Association (AMA),c 2016 |
338 | a print2 rdacarrier | |
520 | a IMPORTANCE Amyotrophic lateral sclerosis (ALS) is a devastating adult-onset neurodegenerative disorder with a poor prognosis and a median survival of 3 years. However, a significant proportion of patients survive more than 10 years from symptom onset. OBJECTIVE To identify gene variants influencing survival in ALS. DESIGN, SETTING, AND PARTICIPANTS This genome-wide association study (GWAS) analyzed survival in data sets from several European countries and the United States that were collected by the Italian Consortium for the Genetics of ALS and the International Consortium on Amyotrophic Lateral Sclerosis Genetics. The study population included 4256 patients with ALS (3125 [73.4%] deceased) with genotype data extended to 7 174 392 variants by imputation analysis. Samples of DNA were collected from January 1, 1993, to December 31, 2009, and analyzed from March 1, 2014, to February 28, 2015. MAIN OUTCOMES AND MEASURES Cox proportional hazards regression under an additive model with adjustment for age at onset, sex, and the first 4 principal components of ancestry, followed bymeta-analysis, were used to analyze data. Survival distributions for the most associated genetic variants were assessed by Kaplan-Meier analysis. RESULTS Among the 4256 patients included in the analysis (2589 male [60.8%] and 1667 female [39.2%]; mean [SD] age at onset, 59 [12] years), the following 2 novel loci were significantly associated with ALS survival: at 10q23 (rs139550538; P = 1.87 x 10(-9)) and in the CAMTA1 gene at 1p36 (rs2412208, P = 3.53 x 10(-8)). At locus 10q23, the adjusted hazard ratio for patients with the rs139550538 AA or AT genotype was 1.61 (95% CI, 1.38-1.89; P = 1.87 x 10(-9)), corresponding to an 8-month reduction in survival compared with TT carriers. For rs2412208 CAMTA1, the adjusted hazard ratio for patients with the GG or GT genotype was 1.17 (95% CI, 1.11-1.24; P = 3.53 x 10(-8)), corresponding to a 4-month reduction in survival compared with TT carriers. CONCLUSIONS AND RELEVANCE This GWAS robustly identified 2 loci at genome-wide levels of significance that influence survival in patients with ALS. Because ALS is a rare disease and prevention is not feasible, treatment that modifies survival is the most realistic strategy. Therefore, identification of modifier genes that might influence ALS survival could improve the understanding of the biology of the disease and suggest biological targets for pharmaceutical intervention. In addition, genetic risk scores for survival could be used as an adjunct to clinical trials to account for the genetic contribution to survival. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
653 | a Motor-neuron disease | |
653 | a ALS | |
653 | a C9ORF72 | |
653 | a Genome-wide association | |
700 | 1 | a Lin, Kuang4 aut |
700 | 1 | a Tiloca, Cinzia4 aut |
700 | 1 | a Rooney, James4 aut |
700 | 1 | a Gellera, Cinzia4 aut |
700 | 1 | a Diekstra, Frank P.4 aut |
700 | 1 | a Ratti, Antonia4 aut |
700 | 1 | a Shatunov, Aleksey4 aut |
700 | 1 | a van Es, Michael A.4 aut |
700 | 1 | a Proitsi, Petroula4 aut |
700 | 1 | a Jones, Ashley4 aut |
700 | 1 | a Sproviero, William4 aut |
700 | 1 | a Chio, Adriano4 aut |
700 | 1 | a McLaughlin, Russell Lewis4 aut |
700 | 1 | a Soraru, Gianni4 aut |
700 | 1 | a Corrado, Lucia4 aut |
700 | 1 | a Stahl, Daniel4 aut |
700 | 1 | a Del Bo, Roberto4 aut |
700 | 1 | a Cereda, Cristina4 aut |
700 | 1 | a Castellotti, Barbara4 aut |
700 | 1 | a Glass, Jonathan D.4 aut |
700 | 1 | a Newhouse, Steven4 aut |
700 | 1 | a Dobson, Richard4 aut |
700 | 1 | a Smith, Bradley N.4 aut |
700 | 1 | a Topp, Simon4 aut |
700 | 1 | a van Rheenen, Wouter4 aut |
700 | 1 | a Meininger, Vincent4 aut |
700 | 1 | a Melki, Judith4 aut |
700 | 1 | a Morrison, Karen E.4 aut |
700 | 1 | a Shaw, Pamela J.4 aut |
700 | 1 | a Leigh, P. Nigel4 aut |
700 | 1 | a Andersen, Peter M.u Umeå universitet,Klinisk neurovetenskap,Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany4 aut0 (Swepub:umu)pean0001 |
700 | 1 | a Comi, Giacomo P.4 aut |
700 | 1 | a Ticozzi, Nicola4 aut |
700 | 1 | a Mazzini, Letizia4 aut |
700 | 1 | a D'Alfonso, Sandra4 aut |
700 | 1 | a Traynor, Bryan J.4 aut |
700 | 1 | a Van Damme, Philip4 aut |
700 | 1 | a Robberecht, Wim4 aut |
700 | 1 | a Brown, Robert H.4 aut |
700 | 1 | a Landers, John E.4 aut |
700 | 1 | a Hardiman, Orla4 aut |
700 | 1 | a Lewis, Cathryn M.4 aut |
700 | 1 | a van den Berg, Leonard H.4 aut |
700 | 1 | a Shaw, Christopher E.4 aut |
700 | 1 | a Veldink, Jan H.4 aut |
700 | 1 | a Silani, Vincenzo4 aut |
700 | 1 | a Al-Chalabi, Ammar4 aut |
700 | 1 | a Powell, John4 aut |
710 | 2 | a Umeå universitetb Klinisk neurovetenskap4 org |
773 | 0 | t JAMA Neurologyd : American Medical Association (AMA)g 73:7, s. 812-820q 73:7<812-820x 2168-6149x 2168-6157 |
856 | 4 | u https://jamanetwork.com/journals/jamaneurology/articlepdf/2525542/noi160035.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-124512 |
856 | 4 8 | u https://doi.org/10.1001/jamaneurol.2016.1114 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view